MX2022001489A - Proceso para la preparacion de una composicion que comprende un polipeptido de proteina d. - Google Patents

Proceso para la preparacion de una composicion que comprende un polipeptido de proteina d.

Info

Publication number
MX2022001489A
MX2022001489A MX2022001489A MX2022001489A MX2022001489A MX 2022001489 A MX2022001489 A MX 2022001489A MX 2022001489 A MX2022001489 A MX 2022001489A MX 2022001489 A MX2022001489 A MX 2022001489A MX 2022001489 A MX2022001489 A MX 2022001489A
Authority
MX
Mexico
Prior art keywords
polypeptide
protein
preparing
composition
relates
Prior art date
Application number
MX2022001489A
Other languages
English (en)
Inventor
Laurent Bernard Jean Strodiot
Bram Vuylsteke
Houer Pierre Sae
Dos Santos Pedro Santana
Arnaud Zuliani
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of MX2022001489A publication Critical patent/MX2022001489A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/07—Bacillus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/104—Pseudomonadales, e.g. Pseudomonas
    • A61K39/1045—Moraxella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Abstract

La presente invención se refiere a un proceso para la preparación de composiciones inmunogénicas. Más particularmente, se refiere a un proceso para la preparación de composiciones líquidas de polipéptido de Proteína D y su uso en la preparación de composiciones inmunogénicas que comprenden polipéptido de Proteína D que pueden usarse en el tratamiento o prevención de una exacerbación aguda de la enfermedad pulmonar obstructiva crónica (EA-EPOC) en un sujeto, por ejemplo, un ser humano.
MX2022001489A 2019-08-05 2020-08-03 Proceso para la preparacion de una composicion que comprende un polipeptido de proteina d. MX2022001489A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19189964 2019-08-05
PCT/EP2020/071761 WO2021023692A1 (en) 2019-08-05 2020-08-03 Process for preparing a composition comprising a protein d polypeptide

Publications (1)

Publication Number Publication Date
MX2022001489A true MX2022001489A (es) 2022-03-02

Family

ID=67544100

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022001489A MX2022001489A (es) 2019-08-05 2020-08-03 Proceso para la preparacion de una composicion que comprende un polipeptido de proteina d.

Country Status (9)

Country Link
US (1) US20230248816A9 (es)
EP (1) EP4009951A1 (es)
JP (1) JP2022543264A (es)
CN (1) CN114245746A (es)
AU (1) AU2020325569B2 (es)
BR (1) BR112021026775A2 (es)
CA (1) CA3148928A1 (es)
MX (1) MX2022001489A (es)
WO (1) WO2021023692A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024017827A1 (en) 2022-07-19 2024-01-25 Glaxosmithkline Biologicals Sa Continuous process for vaccine production

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
DK0812593T4 (da) 1993-03-23 2008-05-13 Smithkline Beecham Biolog Vaccinepræparater indeholdende 3-O-deacyleret monophosphoryllipid-A
PL203917B1 (pl) 1999-03-19 2009-11-30 Glaxosmithkline Biolog Sa Kompozycja immunogenna, sposób jej wytwarzania oraz zastosowanie
CA2618554C (en) 2005-08-10 2017-03-07 Arne Forsgren Ab Interaction of moraxella catarrhalis with epithelial cells, extracellular matrix proteins and the complement system
BRPI0707154B8 (pt) 2006-01-17 2022-12-20 Forsgren Arne composição de vacina
TW201302779A (zh) 2011-04-13 2013-01-16 Glaxosmithkline Biolog Sa 融合蛋白質及組合疫苗
AR090244A1 (es) * 2012-03-08 2014-10-29 Hoffmann La Roche Formulacion de anticuerpo anti-selectina p
TW201620927A (zh) 2014-02-24 2016-06-16 葛蘭素史密斯克藍生物品公司 Ｕｓｐａ２蛋白質構築體及其用途
WO2018178265A1 (en) * 2017-03-31 2018-10-04 Glaxosmithkline Intellectual Property Development Limited Immunogenic composition, use and method of treatment
BR112020001768A2 (pt) * 2017-08-14 2020-09-29 Glaxosmithkline Biologicals S.A. método de reforçar uma resposta imune pré-existente contra haemophilus influenzae e moraxella catarrhalis não tipáveis em um indivíduo, e, protocolo de vacinação.

Also Published As

Publication number Publication date
CA3148928A1 (en) 2021-02-11
EP4009951A1 (en) 2022-06-15
AU2020325569B2 (en) 2024-01-18
AU2020325569A1 (en) 2022-02-24
BR112021026775A2 (pt) 2022-05-10
CN114245746A (zh) 2022-03-25
WO2021023692A1 (en) 2021-02-11
JP2022543264A (ja) 2022-10-11
US20230248816A9 (en) 2023-08-10
US20220288190A1 (en) 2022-09-15

Similar Documents

Publication Publication Date Title
MX2022005291A (es) Vacunas para el tratamiento y prevencion del cancer.
MX2021014007A (es) Proteinas de union a epcam y metodos de uso.
PH12020550051A1 (en) Glp-1 compositions and uses thereof
PH12021550992A1 (en) Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as atr kinase inhibitors
MX2009012950A (es) ANTICUERPOS HUMANIZADOS CONTRA EL GLOBULOMERO Aß (20-42) Y SUS USOS.
MX2022007122A (es) Dominios de repetición de anquirina diseñados con residuos de superficie alterados.
MX2016014187A (es) Adenovirus que comprende una fraccion de union a albumina.
MX2017000378A (es) ANTICUERPOS DE UNION A PROTOFIBRILLAS BETA AMILOIDE (Aß) MEJORADOS.
MX2021003109A (es) Proteina para el tratamiento de enfermedades inflamatorias.
PH12019550241A1 (en) Mic-1 compounds and uses thereof
NZ721015A (en) Mutant fragments of ospa and methods and uses relating thereto
MX2022002635A (es) Anticuerpos anti proteina similar a angiopoyetina 4 y metodos de uso.
EA202192925A1 (ru) Твердые формы ингибитора glyt1
MX2022001488A (es) Composicion inmunogenica.
MX2019003970A (es) Péptidos de arginasa inmunogénicos.
ZA202001568B (en) Methods and compositions for treating chronic lung diseases
MX2022001489A (es) Proceso para la preparacion de una composicion que comprende un polipeptido de proteina d.
EP4218789A3 (en) Compositions for colon cleansing and the treatment of gastrointestnal disorders
MX2020001820A (es) Metodos para reforzar las respuestas inmunitarias.
WO2017049082A3 (en) Compositions comprising pregnancy specific glycoproteins and methods of use thereof
MX2022000484A (es) Anticuerpos contra bssl novedosos.
MX2021011986A (es) Metodos de tratamiento de dolor neuropatico.
EA201891337A3 (ru) Фармацевтическая композиция от нейропатической боли
WO2017168414A8 (en) Iron chelators and combination thereof for the treatment of wolfram syndrome 2
JOP20190178A1 (ar) تركيبة صيدلانية تتضمن مشتق أوكسازين واستخدامها في علاج أو الوقاية من مرض الزهايمر